Bryan Cox
Technik-/Wissenschafts-/F&E-Leiter bei TRISALUS LIFE SCIENCES, INC.
Vermögen: 860 891 $ am 30.04.2024
Profil
Dr. Bryan F.
Cox is a Chief Scientific & Manufacturing Officer at TriSalus Life Sciences, Inc. and a Chief Executive Officer at Nephraegis Therapeutics, Inc.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 12.02.2024 | 86 696 ( 0,32% ) | 860 891 $ | 30.04.2024 |
Aktive Positionen von Bryan Cox
| Unternehmen | Position | Beginn |
|---|---|---|
| TRISALUS LIFE SCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 10.08.2023 |
Nephraegis Therapeutics, Inc.
 Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics, Inc. is a biopharmaceutical company that focuses on developing a family of proprietary drug candidates to prevent and treat acute kidney injury (AKI). The company is based in Lake Forest, IL. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The CEO of the company is Bryan F. Cox. | Vorstandsvorsitzender | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| TRISALUS LIFE SCIENCES, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Nephraegis Therapeutics, Inc.
Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics, Inc. is a biopharmaceutical company that focuses on developing a family of proprietary drug candidates to prevent and treat acute kidney injury (AKI). The company is based in Lake Forest, IL. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The CEO of the company is Bryan F. Cox. | Health Technology |
